Summit Therapeutics PLC (ADR) (SMMT) was Reiterated by Needham to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 30 from a previous price target of $22 . Needham advised their investors in a research report released on Oct 5, 2016.
Many Wall Street Analysts have commented on Summit Therapeutics PLC (ADR). H.C. Wainwright Initiated Summit Therapeutics PLC (ADR) on Sep 16, 2016 to “Buy”, Price Target of the shares are set at $26.
Summit Therapeutics PLC (ADR) opened for trading at $16 and hit $19.75 on the upside on Tuesday, eventually ending the session at $14.35, with a gain of 65.90% or 5.7 points. The heightened volatility saw the trading volume jump to 48,42,395 shares. Company has a market cap of $176 M.
Summit Therapeutics plc formerly Summit Corporation plc is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company’s lead DMD product candidate is SMT C1100 an orally administered small molecule. The Company’s lead CDI product candidate is SMT19969 an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics Inc. Summit (Oxford) Limited Summit (Wales) Limited and MuOx Limited among others.